Attached files
file | filename |
---|---|
10-K - 10-K - Cardiff Oncology, Inc. | trov-123119x10k.htm |
EX-32.2 - EXHIBIT 32.2 - Cardiff Oncology, Inc. | exhibit322q42019.htm |
EX-32.1 - EXHIBIT 32.1 - Cardiff Oncology, Inc. | exhibit321q42019.htm |
EX-31.2 - EXHIBIT 31.2 - Cardiff Oncology, Inc. | exhibit312q42019.htm |
EX-31.1 - EXHIBIT 31.1 - Cardiff Oncology, Inc. | exhibit311q42019.htm |
EX-4.16 - EXHIBIT 4.16 - Cardiff Oncology, Inc. | exhibit416q42019.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Trovagene, Inc.
San Diego, California
We hereby consent to the incorporation by reference in the Registration Statements on Form S-1 (Nos. 333-234442, 333-233568 and 333-224808), Form S-3 (Nos. 333-232321, 333-229693, 333-211705 and 333-208010) and Form S-8 (Nos. 333-232363, 333-226172, 333-220060, 333-211846, 333-205424 and 333-190415) of Trovagene, Inc. (the “Company”) of our report dated February 27, 2020, relating to the financial statements, which appears in this Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
/s/ BDO USA, LLP
San Diego, California
February 27, 2020